» Articles » PMID: 33982583

Application of Modified Mesenchymal Stem Cells Transplantation in the Treatment of Liver Injury

Overview
Journal Physiol Res
Specialty Physiology
Date 2021 May 13
PMID 33982583
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Acute and chronic hepatitis, cirrhosis, and other liver diseases pose a serious threat to human health; however, liver transplantation is the only reliable treatment for the terminal stage of liver diseases. Previous researchers have shown that mesenchymal stem cells (MSCs) are characterized by differentiation and paracrine effects, as well as anti-oxidative stress and immune regulation functions. When MSCs are transplanted into animals, they migrate to the injured liver tissue along with the circulation, to protect the liver and alleviate the injury through the paracrine, immune regulation and other characteristics, making mesenchymal stem cell transplantation a promising alternative therapy for liver diseases. Although the efficacy of MSCs transplantation has been confirmed in various animal models of liver injury, many researchers have also proposed various pretreatment methods to improve the efficacy of mesenchymal stem cell transplantation, but there is still lack a set of scientific methods system aimed at improving the efficacy of transplantation therapy in scientific research and clinical practice. In this review, we summarize the possible mechanisms of MSCs therapy and compare the existing methods of MSCs modification corresponding to the treatment mechanism, hoping to provide as a reference to help future researchers explore a safe and simple transplantation strategy.

Citing Articles

miR-9-5p and miR-221-3p Promote Human Mesenchymal Stem Cells to Alleviate Carbon Tetrachloride-Induced Liver Injury by Enhancing Human Mesenchymal Stem Cell Engraftment and Inhibiting Hepatic Stellate Cell Activation.

He L, Xu J, Huang P, Bai Y, Chen H, Xu X Int J Mol Sci. 2024; 25(13).

PMID: 39000343 PMC: 11241704. DOI: 10.3390/ijms25137235.


Development and characterization of a chronic hepatitis B murine model with a mutation in the START codon of an HBV polymerase.

Vanekova L, Polidarova M, Charvat V, Vavrina Z, Veverka V, Birkus G Physiol Res. 2022; 72(1):37-47.

PMID: 36545874 PMC: 10069812. DOI: 10.33549/physiolres.934979.

References
1.
Chen L, Zhang C, Chen L, Wang X, Xiang B, Wu X . Human Menstrual Blood-Derived Stem Cells Ameliorate Liver Fibrosis in Mice by Targeting Hepatic Stellate Cells via Paracrine Mediators. Stem Cells Transl Med. 2017; 6(1):272-284. PMC: 5442725. DOI: 10.5966/sctm.2015-0265. View

2.
Puglisi M, Tesori V, Lattanzi W, Piscaglia A, Gasbarrini G, DUgo D . Therapeutic implications of mesenchymal stem cells in liver injury. J Biomed Biotechnol. 2012; 2011:860578. PMC: 3250695. DOI: 10.1155/2011/860578. View

3.
Volarevic V, Nurkovic J, Arsenijevic N, Stojkovic M . Concise review: Therapeutic potential of mesenchymal stem cells for the treatment of acute liver failure and cirrhosis. Stem Cells. 2014; 32(11):2818-23. DOI: 10.1002/stem.1818. View

4.
Zheng J, Chen L, Lu T, Zhang Y, Sui X, Li Y . MSCs ameliorate hepatocellular apoptosis mediated by PINK1-dependent mitophagy in liver ischemia/reperfusion injury through AMPKα activation. Cell Death Dis. 2020; 11(4):256. PMC: 7171190. DOI: 10.1038/s41419-020-2424-1. View

5.
Cho K, Woo S, Seoh J, Han H, Ryu K . Mesenchymal stem cells restore CCl4-induced liver injury by an antioxidative process. Cell Biol Int. 2012; 36(12):1267-74. DOI: 10.1042/CBI20110634. View